Recent single-cell analyses of T cell populations across various breast cancer subtypes provide additional insights, revealing that ER+ breast cancers have a lower diversity in the T cell receptor repertoire, which aligns with the limited presence of neoantigens in ER+ cancer when compared to TNBC and HER2+ cancers [61,62]. This evidence concerns the gene ERBB2 and breast carcinoma.